Last Updated: November 16, 2026

CLINICAL TRIALS PROFILE FOR TEBIPENEM PIVOXIL HYDROBROMIDE

« Back to Dashboard


All Clinical Trials for tebipenem pivoxil hydrobromide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03788967 ↗ Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Completed Spero Therapeutics Phase 3 2019-06-03 The key purpose of this study is to evaluate the efficacy, safety and pharmacokinetics (PK) of TBPM-PI-HBr compared to IV ertapenem, in subjects with Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP).
NCT04178577 ↗ Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function Completed Spero Therapeutics Phase 1 2019-12-06 Evaluation of the pharmacokinetics (PK) of TBPM-PI-HBr in subjects with normal renal function, subjects with various degrees of renal insufficiency, and subjects with end-stage renal disease (ESRD) receiving hemodialysis (HD) therapy.
NCT04238195 ↗ A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects Completed Celerion Phase 1 2020-01-19 This is a randomized, double-blind (with respect to Tebipenem pivoxil hydrobromide [TBPM-PI-HBr]/placebo only), placebo- and active-control, single-dose, 4-way crossover study that will enroll 24 healthy adult male and female subjects. There will be a washout period of at least 7 days between dosing in each period and each subject will receive all 4 treatments over 4 periods in a crossover study design.
NCT04238195 ↗ A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects Completed Spero Therapeutics Phase 1 2020-01-19 This is a randomized, double-blind (with respect to Tebipenem pivoxil hydrobromide [TBPM-PI-HBr]/placebo only), placebo- and active-control, single-dose, 4-way crossover study that will enroll 24 healthy adult male and female subjects. There will be a washout period of at least 7 days between dosing in each period and each subject will receive all 4 treatments over 4 periods in a crossover study design.
NCT04368585 ↗ Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects Completed Spero Therapeutics Phase 1 2020-07-01 To assess the effect of a single dose of aluminum hydroxide/magnesium hydroxide/simethicone and omeprazole on the pharmacokinetics (PK) of TBPM, following a single dose of TBPM-PI-HBr in healthy adult subjects.
NCT04376554 ↗ Effect of Tebipenem on Normal Human Intestinal Microbiota Completed Iqvia Pty Ltd Phase 1 2020-02-10 The overall purpose of this study is to support the development of an oral formulation of TBPM-PI-HBr by assessing the potential ecological effects of tebipenem on the normal intestinal microbiota as compared to the effects of oral amoxicillin-clavulanate.
NCT04376554 ↗ Effect of Tebipenem on Normal Human Intestinal Microbiota Completed Spero Therapeutics Phase 1 2020-02-10 The overall purpose of this study is to support the development of an oral formulation of TBPM-PI-HBr by assessing the potential ecological effects of tebipenem on the normal intestinal microbiota as compared to the effects of oral amoxicillin-clavulanate.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for tebipenem pivoxil hydrobromide

Condition Name

Condition Name for tebipenem pivoxil hydrobromide
Intervention Trials
Healthy Volunteers 6
Acute Pyelonephritis 2
TQT Study 1
Urinary Tract Infection 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for tebipenem pivoxil hydrobromide
Intervention Trials
Infections 3
Communicable Diseases 3
Pyelonephritis 2
Infection 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for tebipenem pivoxil hydrobromide

Trials by Country

Trials by Country for tebipenem pivoxil hydrobromide
Location Trials
United States 10
Romania 2
Slovakia 2
Hungary 2
Poland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for tebipenem pivoxil hydrobromide
Location Trials
Arizona 3
Florida 3
Utah 1
Connecticut 1
Wisconsin 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for tebipenem pivoxil hydrobromide

Clinical Trial Phase

Clinical Trial Phase for tebipenem pivoxil hydrobromide
Clinical Trial Phase Trials
PHASE1 1
Phase 3 2
Phase 1 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for tebipenem pivoxil hydrobromide
Clinical Trial Phase Trials
COMPLETED 8
Not yet recruiting 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for tebipenem pivoxil hydrobromide

Sponsor Name

Sponsor Name for tebipenem pivoxil hydrobromide
Sponsor Trials
Spero Therapeutics 10
GlaxoSmithKline 2
Hartford Hospital 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for tebipenem pivoxil hydrobromide
Sponsor Trials
Industry 15
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.